Show simple item record

dc.contributor.authorShivendu, Shivendu et al.
dc.description.abstractThe goal of this paper is to showcase that the COVID-19 disease pattern is evolving and to study the relationship between mandatory BCG policy and caseload/million or death/per million. We analyze seven recent publications on the impact of BCG vaccinations on the development of COVID19 illness and extend presented findings using the latest data from April 10, 2020. We analyze data from 98 countries and we extend existing models by adding the dimension of COVID-19-related testing conducted by the analyzed countries. Similarly to prior studies, we find that COVID-19 attributable case and death incidences across countries share a relationship with the BCG vaccination inclusion in the national immunization program of a country when testing is not taken into consideration. However, this relationship vanishes when we add the dimension of testing. We observe that case and death incidences conditional on testing do not get affected by the BCG vaccination inclusion in the national immunization program of a country. Therefore, we show that there is no statistical evidence to support the assertion that inclusion of BCG vaccination in national immunization program (NIP) has any impact of COVID 19 infections (cases) or mortality.en_US
dc.subjectBCG Vaccineen_US
dc.subjectSystematic Reviewen_US
dc.subjectCoronavirus Infectionsen_US
dc.subjectLaboratory Testen_US
dc.subjectImmunization Programsen_US
dc.titleIs there evidence that BCG vaccination has non-specific protective effects for COVID 19 infections or is it an illusion created by lack of testing?en_US
eihealth.countryGlobal (WHO/OMS)en_US
eihealth.categoryEpidemiology and epidemiological studiesen_US
eihealth.typePublished Articleen_US
eihealth.maincategorySlow Spread / Reducir la Dispersiónen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record